1. Home
  2. SNGX vs YDKG Comparison

SNGX vs YDKG Comparison

Compare SNGX & YDKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.37

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Yueda Digital Holding Class A Ordinary Share

YDKG

Yueda Digital Holding Class A Ordinary Share

HOLD

Current Price

$0.95

Market Cap

4.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
YDKG
Founded
1987
2005
Country
United States
China
Employees
N/A
17
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.8M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
SNGX
YDKG
Price
$0.37
$0.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
608.4K
86.2K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
N/A
EPS
N/A
N/A
Revenue
$119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.02
52 Week High
$6.23
$3.90

Technical Indicators

Market Signals
Indicator
SNGX
YDKG
Relative Strength Index (RSI) 37.48 60.18
Support Level $0.28 $0.81
Resistance Level $0.41 $1.04
Average True Range (ATR) 0.02 0.06
MACD 0.01 0.01
Stochastic Oscillator 15.68 100.00

Price Performance

Historical Comparison
SNGX
YDKG

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

Share on Social Networks: